Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1
Go back to Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1| Merck & Co. (NYSE: MRK) | Delayed: 115.48 +1.61 (1.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $113.87 | 52 Week High | $65.46 | |||
| Open | $113.97 | 52 Week Low | $47.97 | |||
| Day High | $115.63 | P/E | 78.56 | |||
| Day Low | $113.00 | EPS | $1.47 | |||
| Volume | 10,593,825 | |||||
